Zhe Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhe Zhang has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Hua Liang
Hebei Key Laboratory of Chinese Medicine Research on Cardio-Cerebrovascular Disease, Hebei University of Chinese Medicine, No. 3 Xingyuan Road, Luquan District, Shijiazhuang 050200, China
1 shared publication Junbiao Tian
The First Affiliated Hospital of Hebei University of Traditional Chinese Medicine
1 shared publication- Ping Gao
Hebei Key Laboratory of Chinese Medicine Research on Cardio-Cerebrovascular Disease, Hebei University of Chinese Medicine, No. 3 Xingyuan Road, Luquan District, Shijiazhuang 050200, China
1 shared publication Pingping Zhou
The First Affiliated Hospital of Hebei University of Traditional Chinese Medicine
1 shared publicationRui Shi
Hebei University of Chinese Medicine
1 shared publicationTian Fu
Hebei University of Chinese Medicine
1 shared publication
Latest Publications
- Open Access
- 10 November 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1996341
Regulated cell death in cerebral infarction: a switch-aware framework from molecular mechanisms to targeted therapy
Background: Cerebral infarction remains a leading cause of death and long-term disability. Although reperfusion therapy has transformed early management, its benefit is limited by narrow time windows, and most neuroprotective monotherapies have failed in translation. Rather than isolated endpoints, apoptosis, necroptosis, pyroptosis, ferroptosis and autophagy-related processes form a dynamically interconnected network; cuproptosis remains an exploratory candidate. Methods: This narrative synthesis (not a systematic/meta-analysis) drew on primary research and authoritative nomenclature sources on the major regulated cell death modalities in cerebral ischemia/reperfusion, retrieved from PubMed, Embase, and Web of Science through August 2026. The search was not pre-registered, and no formal risk-of-bias assessment was performed. Results: Post-ischemic cell death is organized around three convertible molecular switch hubs—caspase-8/RIPK, NCOA4ferritinophagy, and Nrf2 — with gasdermin-D (GSDMD)-mediated pyroptosis as a downstream effector. These hubs map onto the ischemic core, penumbra, and reperfused territory over 0–72 h, and their interconversion helps explain the limited efficacy of single-executor monotherapies. We further assess biomarkers and pharmacological interventions, and extend the framework through the gut-brain axis, where intestinal barrier dysfunction and dysbiosis prime the same central NLRP3, RIPK, and Nrf2 switches. Cuproptosis is retained only as a hypothesis-generating candidate. Clinically meaningful neuroprotection will require mechanism-based, time-and compartment-specific combination strategies. Modality-specific composite biomarker panels paired with time-sensitive therapies offer the most tractable route to patient stratification; the gut-derived input requires prospective validation. Conclusion: Framing post-ischemic cell death through convertible switches reframes neuroprotection as a problem of network timing and patient stratification. This switch-aware framework is prospective and falsifiable, generating testable hypotheses for future preclinical and clinical studies.
- 10 November 2026
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 14, 1996341
Open AccessRegulated cell death in cerebral infarction: a switch-aware framework from molecular mechanisms to targeted therapy
Background: Cerebral infarction remains a leading cause of death and long-term disability. Although reperfusion therapy has transformed early management, its benefit is limited by narrow time windows, and most neuroprotective monotherapies have failed in translation. Rather than isolated endpoints, apoptosis, necroptosis, pyroptosis, ferroptosis and autophagy-related processes form a dynamically interconnected network; cuproptosis remains an exploratory candidate. Methods: This narrative synthesis (not a systematic/meta-analysis) drew on primary research and authoritative nomenclature sources on the major regulated cell death modalities in cerebral ischemia/reperfusion, retrieved from PubMed, Embase, and Web of Science through August 2026. The search was not pre-registered, and no formal risk-of-bias assessment was performed. Results: Post-ischemic cell death is organized around three convertible molecular switch hubs—caspase-8/RIPK, NCOA4ferritinophagy, and Nrf2 — with gasdermin-D (GSDMD)-mediated pyroptosis as a downstream effector. These hubs map onto the ischemic core, penumbra, and reperfused territory over 0–72 h, and their interconversion helps explain the limited efficacy of single-executor monotherapies. We further assess biomarkers and pharmacological interventions, and extend the framework through the gut-brain axis, where intestinal barrier dysfunction and dysbiosis prime the same central NLRP3, RIPK, and Nrf2 switches. Cuproptosis is retained only as a hypothesis-generating candidate. Clinically meaningful neuroprotection will require mechanism-based, time-and compartment-specific combination strategies. Modality-specific composite biomarker panels paired with time-sensitive therapies offer the most tractable route to patient stratification; the gut-derived input requires prospective validation. Conclusion: Framing post-ischemic cell death through convertible switches reframes neuroprotection as a problem of network timing and patient stratification. This switch-aware framework is prospective and falsifiable, generating testable hypotheses for future preclinical and clinical studies.
- Open Access
- 29 March 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (4) , 547
Mechanism of Astragaloside IV Against Cerebral Ischemia–Reperfusion Injury: Inhibiting Neuronal Apoptosis via the CytC/Apaf-1 Mitochondrial Pathway
Background: Neuronal apoptosis is the core pathological mechanism of cerebral ischemic–reperfusion injury (CIRI); although Astragaloside IV (AS-IV) has demonstrated neuroprotective activity against CIRI, its specific molecular mechanisms underlying the regulation of this apoptosis-related pathway remain to be systematically elucidated. Methods: We establish an in vivo model of middle cerebral artery occlusion/reperfusion (MCAO/R) in rats and an in vitro model of oxygen–glucose deprivation/reperfusion (OGD/R) in PC12 cells. Six core apoptotic proteins, including CytC, Apaf-1, BAX, Bcl-2, Caspase3, and Caspase9, were detected using neurological function scoring, TTC/HE/Nissl staining, TUNEL staining, Western blot, and immunofluorescence techniques. Molecular docking and molecular dynamics simulation were utilized to analyze the binding affinity between AS-IV and the aforementioned apoptotic proteins. Results: Molecular docking and dynamics simulation demonstrated AS-IV stably binds six core apoptotic proteins, and comparative analysis with target-specific reference ligands identified Apaf-1 as its primary target with the most favorable binding properties. In rat MCAO/R models, AS-IV alleviated neurological deficits, reduced cerebral infarct volume and improved brain pathological damage; in PC12 cell OGD/R models, it decreased neuronal apoptosis. Western blot and immunofluorescence confirmed AS-IV downregulated pro-apoptotic proteins (cytoplasmic CytC, Apaf-1, BAX, cleaved-Caspase9/3) and upregulated anti-apoptotic Bcl-2. Conclusions: This study clarifies the anti-apoptotic molecular mechanism of AS-IV, it alleviates CIRI by targeting the CytC/Apaf-1 mitochondrial apoptotic pathway.
- 29 March 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (4) , 547
Open AccessMechanism of Astragaloside IV Against Cerebral Ischemia–Reperfusion Injury: Inhibiting Neuronal Apoptosis via the CytC/Apaf-1 Mitochondrial Pathway
Background: Neuronal apoptosis is the core pathological mechanism of cerebral ischemic–reperfusion injury (CIRI); although Astragaloside IV (AS-IV) has demonstrated neuroprotective activity against CIRI, its specific molecular mechanisms underlying the regulation of this apoptosis-related pathway remain to be systematically elucidated. Methods: We establish an in vivo model of middle cerebral artery occlusion/reperfusion (MCAO/R) in rats and an in vitro model of oxygen–glucose deprivation/reperfusion (OGD/R) in PC12 cells. Six core apoptotic proteins, including CytC, Apaf-1, BAX, Bcl-2, Caspase3, and Caspase9, were detected using neurological function scoring, TTC/HE/Nissl staining, TUNEL staining, Western blot, and immunofluorescence techniques. Molecular docking and molecular dynamics simulation were utilized to analyze the binding affinity between AS-IV and the aforementioned apoptotic proteins. Results: Molecular docking and dynamics simulation demonstrated AS-IV stably binds six core apoptotic proteins, and comparative analysis with target-specific reference ligands identified Apaf-1 as its primary target with the most favorable binding properties. In rat MCAO/R models, AS-IV alleviated neurological deficits, reduced cerebral infarct volume and improved brain pathological damage; in PC12 cell OGD/R models, it decreased neuronal apoptosis. Western blot and immunofluorescence confirmed AS-IV downregulated pro-apoptotic proteins (cytoplasmic CytC, Apaf-1, BAX, cleaved-Caspase9/3) and upregulated anti-apoptotic Bcl-2. Conclusions: This study clarifies the anti-apoptotic molecular mechanism of AS-IV, it alleviates CIRI by targeting the CytC/Apaf-1 mitochondrial apoptotic pathway.